The disclosed RAIN token valuation (~$1.16B) dwarfs Enlivex's $189M market cap, creating a potential arbitrage opportunity if the market re-rates the stock toward the treasury value. However, RAIN token liquidity and price volatility are key risks — monitor token price action and any future RAIN token sales or lock-up disclosures. The $100M liquidity commitment to Rain's protocol is a positive catalyst for the token's ecosystem credibility.
Price Chart
Executive Summary
Enlivex disclosed that its RAIN token holdings were valued at approximately $1.16 billion as of May 27, 2026, representing 79.57 billion tokens. The Rain Foundation also announced a $100 million liquidity commitment to the Rain protocol, positioning it as the third-largest prediction market protocol globally by TVL. This filing updates the company's treasury portfolio but provides no clinical or operational financial data.
Key Facts
- Enlivex held 79,568,550,005 RAIN tokens valued at approximately $1.16 billion as of May 27, 2026.
- The Rain Foundation announced a $100 million liquidity commitment to Rain's prediction markets protocol.
- Rain protocol has over 29,000 users and has burned more than 100 million RAIN tokens through buyback-and-burn as of April 27, 2026.
- Rain is now the third-largest prediction market protocol globally by Total Value Locked (TVL), behind Polymarket (~$450M TVL).
- Five industry leaders were appointed to the Rain Foundation's advisory board.
- Enlivex's market cap is approximately $189 million, meaning the RAIN holdings value (~$1.16B) is over 6x the company's equity market cap.
Financial Impact
RAIN token holdings valued at approximately $1.16 billion, compared to Enlivex's $189M market cap, implying the treasury asset alone is worth ~6.1x the company's equity value.
Risk Factors
- RAIN token price is highly volatile and may not sustain the valuation used in the disclosure.
- The $1.16B valuation is based on a single date's market price; actual realizable value upon sale could be materially lower.
- Enlivex's clinical-stage biotech operations (Allocetra) have no approved products or disclosed revenue, adding fundamental risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-061765 |
| Document: ea0292428-6k_enlivex.htm | 0001213900-26-061765 |
| Document: 0001213900-26-061765-index-headers.html | 0001213900-26-061765 |
| Document: 0001213900-26-061765-index.html | 0001213900-26-061765 |
| Document: 0001213900-26-061765.txt | 0001213900-26-061765 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.1734 | awaiting T+5 | — | $2.56 (−1379.12%) |
Oct 22, 2026 5d ago | 6-K | $0.1734 | awaiting T+5 | — | $2.56 (+1379.12%) |
Oct 22, 2026 5d ago | Press Release | $0.1734 | awaiting T+5 | — | $2.56 (+1379.12%) |
Oct 19, 2026 8d ago | 6-K | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.56 (−1139.03%) |
Oct 19, 2026 8d ago | Press Release | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.56 (−1139.03%) |
Sep 25, 2026 4w ago | 6-K | $0.5140 $0.3620 | ▼ −29.57% | ▼ −30.78% | $2.56 (+398.99%) |
Sep 22, 2026 5w ago | 6-K | $0.6464 $0.4801 | ▼ −25.73% | ▼ −24.54% | $2.56 (+296.78%) |
Aug 14, 2026 10w ago | EFFECT | $1.58 $1.47 | ▼ −6.96% | ▼ −5.59% | $2.56 (+62.33%) |
Jul 30, 2026 12w ago | 6-K | $1.95 $1.98 | ▲ +1.54% | ▼ −2.08% | $2.56 (+31.53%) |
Jul 29, 2026 12w ago | 6-K | $2.25 $2.18 | ▼ −3.11% | ▼ −8.64% | $2.56 (+13.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers